RecruitingPhase 3NCT06023706
Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.
Phase 3 Confirmatory, Randomised 1:1 Double-blind, Placebo-controlled Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.
Sponsor
Nantes University Hospital
Enrollment
188 participants
Start Date
Nov 8, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objective is to demonstrate the analgesic effect at day 60 of 8% capsaicin patch (Qutenza) for the treatment of patients with coccygodyinia.
Eligibility
Min Age: 18 Years
Inclusion Criteria12
- >18 years old at the pre-inclusion visit
- Presenting with chronic coccygodynia: pain in the coccygeal region, increased by sitting and or when rising from a sitting position and pain over the last ten days of intensity greater than or equal to four on the eleven-point numerical scale (from zero to ten) and having been present for more than 3 months.
- Failure of previous treatments: NSAIDs, pressure-relieving cushions and/or infiltration or having a contraindication to these treatments, or not wishing to receive these treatments
- Have never been treated with an 8% capsaicin patch for this indication
- With at least one clinical sign suggestive of neuropathic pain (burning, painful cold, numbness, tingling, electric discharge, allodynia of the gluteal groove, allodynia to pressure on the coccyx)
- Proficiency in reading and writing the French language
- Be affiliated to the social security system
- Have signed an informed consent form
- be using adequate contraceptive measures, and have a negative pregnancy test (specify if urine or blood test) prior to receiving the first dose of trial medication;
- or be post-menopausal (aged over 50 with amenorrhoea for at least 12 months after stopping all exogenous hormonal treatments)
- or (if under 50) have been in amenorrhoea for at least 12 months after stopping all exogenous hormone treatments and with luteinising hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels.
- or have undergone irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).
Exclusion Criteria6
- Coccygodynia accompanied by a dermatological lesion in the intergluteal cleft (psoriasis, pilodinial cyste, wound)
- Patients with other major pain disorders likely to interfere with pain assessment
- Hypersensitivity to capsaicin or to one of the excipients
- Adults under legal protection (guardianship, curatorship, legal protection)
- Pregnant or breast-feeding women
- Patients who have undergone total coccygectomy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCapsaicin 179 Mg Cutaneous Patch
1 patch applied once for 1 hour
DRUGCapsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
1 patch applied once for 1 hour
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06023706
Related Trials
rTMS Efficacy Coupled With Mirror Therapy
NCT048671872 locations
Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to Reduce Pain and Improve Physical Function.
NCT074033311 location
Thalamic-Burst-DBS for Neuropathic Pain
NCT052044721 location
Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain
NCT075668061 location
Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
NCT069156621 location